MindMed Reports Completion Of End-of-phase 2 Meeting With FDA; Says Reached Alignment On Phase 3 Development Strategy For MM120 In Generalized Anxiety Disorder
Portfolio Pulse from Benzinga Newsdesk
MindMed has completed an end-of-phase 2 meeting with the FDA and reached alignment on the Phase 3 development strategy for MM120 in treating Generalized Anxiety Disorder (GAD). The company plans to initiate the Phase 3 clinical program in the second half of this year.
June 20, 2024 | 11:13 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MindMed has successfully completed an end-of-phase 2 meeting with the FDA and has aligned on the Phase 3 development strategy for MM120 in Generalized Anxiety Disorder. The company is on track to start Phase 3 trials in the second half of this year.
The completion of the end-of-phase 2 meeting with the FDA and alignment on the Phase 3 strategy is a significant milestone for MindMed. This progress indicates regulatory support and a clear path forward for the development of MM120, which is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100